Keratoacanthoma centrifugum marginatum: A diagnostic and therapeutic challenge

Cutis

Volumn 73, Issue 4, 2004, Pages 257-262

  Divers, Allison K ^a   Correale, Dana ^b   Lee, Jason B ^a,c  

^a Pennsylvania Hospital ^*  (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUOROURACIL; IMIQUIMOD; ISOTRETINOIN; METHOTREXATE;

AGED; ANAMNESIS; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; HUMAN; KERATOACANTHOMA; KERATOACANTHOMA CENTRIFUGUM MARGINATUM; LABORATORY TEST; MALE; SKIN DISEASE;

AGED; DERMATOLOGIC AGENTS; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOTRETINOIN; KERATOACANTHOMA; LEG DERMATOSES; MALE; TREATMENT FAILURE;

EID: 2342467317     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Eliezri YD, Libow L. Multinodular keratoacanthoma. J Am Acad Dermatol. 1988;19:826-830.
2. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol. 1994;30:1-19.
3. Weedon D, Barnett L. Keratoacanthoma centrifugum marginatum. Arch Dermatol. 1975;111:1024-1026.
4. Dei Rossi C, Peserico A, Simonetto D. Keratoacanthoma centrifugum marginatum. Arch Dermatol. 1977;113:110.
5. Peteiro MC, Caeiro JL, Toribio J. Keratoacanthoma centrifugum marginatum versus low-grade squamous cell carcinoma. Dermatologica. 1985;170:221-224.
6. Benest L, Kaplan RP, Salit R, et al. Keratoacanthoma centrifugum marginatum of the lower extremity treated with Mohs micrographic surgery. J Am Acad Dermatol. 1994;31:501-502.
7. Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med. 1987;107:499-502.
8. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633-1637.
9. Peck GL, DiGiovanna JJ, Samoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol. 1988;19:176-185.
10. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84:328-332.
11. Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6:957-961.
12. Wong WYL, Kolbusz RV, Goldberg LH. Treatment of a recurrent keratoacanthoma with oral isotretinoin. Int J Dermatol. 1994;33:579-583.
13. Schaller M, Korting HC, Wolff H, et al. Multiple keratoacanthomas, giant keratoacanthoma and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Derm Venereol. 1996;76:40-42.
14. Street ML, White JW Jr, Gibson LE. Multiple keratoacanthomas treated with oral retinoids. J Am Acad Dermatol. 1990;23:862-866.
15. Benoldi D, Alinovi A. Multiple persistent keratoacanthomas: treatment with oral etretinate. J Am Acad Dermatol. 1984;10:1035-1038.
16. Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol. 1991;25:1017-1023.
17. Hurst LN, Gan BS. Intralesional methotrexate in keratoacanthoma of the nose. Br J Plast Surg. 1995;48:243-246.
18. Cuesta-Romero C, de Grado-Pena J. Intralesional methotrexate in solitary keratoacanthoma. Arch Dermatol. 1998;134:513-514.
19. Marks R, Gebauer K, Shumack S, et al, for the Australasian Multicentre Trial Group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-813.
20. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 2001;27:561-564.
21. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 2002;46:545-548.
22. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
23. Viviano E, Sorce M, Mantegna M. Solitary keratoacanthomas in immunocompetent patients: no detection of papillomavirus DNA by polymerase chain reaction. New Microbiol. 2001;24:295-297.
24. Stockfleth E, Meinke B, Arndt R, et al. Identification of DNA sequences of both genital and cutaneous HPV types in a small number of keratoacanthomas of nonimmunosuppressed patients. Dermatology. 1999;198:122-125.
25. Hsi ED, Svoboda-Newman SM, Stern RA, et al. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction. Am J Dermatopathol. 1997;19:10-15.
26. Lu S, Syrjanen SL, Havu VK, et al. Known HPV types have no association with keratoacanthomas. Arch Dermatol Res. 1996;288:129-132.
27. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47:390-398.
28. Goette DK, Odom RB, Arrott JW, et al. Treatment of keratoacanthoma with topical application of fluorouracil. Arch Dermatol. 1982;118:309-311.
29. Goette DK. Treatment of keratoacanthoma with topical fluorouracil. Arch Dermatol. 1983;119:951-953.
30. Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 2000;44:82-85.
31. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332-342.
32. Beham A, Regauer S, Soyer HP, et al. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998;5:269-280.
33. Piscioli F, Boi S, Zumiani G, et al. A gigantic, metastasizing keratoacanthoma, report of a case and discussion on classification. Am J Dermatopathol. 1984;6:123-129.
34. Perez MI, Robins P, Biria S, et al. P53 oncoprotein expression and gene mutations in some keratoacanthomas. Arch Dermatol. 1997;133:189-193.
35. Patel A, Halliday GM, Cooke BE, et al. Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol. 1994;131:789-798.
36. Flannery GR, Muller HK. Immune response to human keratoacanthoma. Br J Dermatol. 1979;101:625-632.
37. LeBoit PE. Can we understand keratoacanthoma? Am J Dermatopathol. 2002;24:166-168.